Work

Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Year: 2025

Type: article

Study design: Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(25)01073-6

Authors: Mazen Noureddin, Juan P Frias, Guy W Neff, K Jean Lucas, Cynthia Behling, Pierre Bedossa, Julie Dubourg, Doreen Chan, Mark Burch, Erica Fong, Brittany de Temple, Matt Minerva, Kim Barrett, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale

Institutions: Houston Methodist, Velocity Clinical Research (United States), Lucas Research

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413269980

FWCI: 47.75

Cites: 30

Cited by: 79

Related to: 10